To deplete or not deplete: enriching MNCs for CAR-T cell therapies through platelet depletion

Enriching mononuclear cells (MNCs) by removing other cell types and contaminants is a critical step in CAR T cell therapy production. But do you know why, how, and when you should carry out platelet depletion to achieve successful T-cell enrichment?

Watch the video to learn:

• How a platelet removal step upstream — rather than downstream — of density gradient separation can reduce the amount of red blood cell contamination
• Why optimal mononuclear cell enrichment is critical to the successful start of a standard autologous CAR-T manufacturing process
• How you can minimize the risk of contamination, operator variability, and errors — while also reducing procedure time – with a closed and automated system for both platelet removal and density gradient separation